Glucose-lowering therapies with proven CV and renal prognostic benefits independent of glycaemia in people with type 2 diabetes such as glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors should be prioritised and their use in combination be considered [3, 125, 126]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.